Literature DB >> 16873241

A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.

Heidi E Drummer1, Irene Boo, Anne L Maerz, Pantelis Poumbourios.   

Abstract

The hepatitis C virus (HCV) glycoproteins E1 and E2 form a heterodimer that mediates CD81 receptor binding and viral entry. In this study, we used site-directed mutagenesis to examine the functional role of a conserved G436WLAGLFY motif of E2. The mutants could be placed into two groups based on the ability of mature virion-incorporated E1E2 to bind the large extracellular loop (LEL) of CD81 versus the ability to mediate cellular entry of pseudotyped retroviral particles. Group 1 comprised E2 mutants where LEL binding ability largely correlated with viral entry ability, with conservative and nonconservative substitutions (W437 L/A, L438A, L441V/F, and F442A) inhibiting both functions. These data suggest that Trp-437, Leu-438, Leu-441, and Phe-442 directly interact with the LEL. Group 2 comprised E2 glycoproteins with more conservative substitutions that lacked LEL binding but retained between 20% and 60% of wild-type viral entry competence. The viral entry competence displayed by group 2 mutants was explained by residual binding by the E2 receptor binding domain to cellular full-length CD81. A subset of mutants maintained LEL binding ability in the context of intracellular E1E2 forms, but this function was largely lost in virion-incorporated glycoproteins. These data suggest that the CD81 binding site undergoes a conformational transition during glycoprotein maturation through the secretory pathway. The G436P mutant was an outlier, retaining near-wild-type levels of CD81 binding but lacking significant viral entry ability. These findings indicate that the G436WLAGLFY motif of E2 functions in CD81 binding and in pre- or post-CD81-dependent stages of viral entry.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873241      PMCID: PMC1563787          DOI: 10.1128/JVI.00029-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Structure-function analysis of hepatitis C virus envelope-CD81 binding.

Authors:  R Petracca; F Falugi; G Galli; N Norais; D Rosa; S Campagnoli; V Burgio; E Di Stasio; B Giardina; M Houghton; S Abrignani; G Grandi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J Dubuisson; C Maidens; R Harrop; G R Guile; P Borrow; J A McKeating
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.

Authors:  A Wack; E Soldaini; C Tseng; S Nuti; G Klimpel; S Abrignani
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

4.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

Authors:  Ania Owsianka; Reginald F Clayton; Lawrence D Loomis-Price; Jane A McKeating; Arvind H Patel
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

Review 5.  Cell entry of hepatitis C virus.

Authors:  Birke Bartosch; François-Loïc Cosset
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

6.  Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

Authors:  A Higginbottom; E R Quinn; C C Kuo; M Flint; L H Wilson; E Bianchi; A Nicosia; P N Monk; J A McKeating; S Levy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  A model for the hepatitis C virus envelope glycoprotein E2.

Authors:  A T Yagnik; A Lahm; A Meola; R M Roccasecca; B B Ercole; A Nicosia; A Tramontano
Journal:  Proteins       Date:  2000-08-15

8.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

9.  Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Authors:  Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R Maurizia Brunetto; Ferruccio Bonino; Sergio Abrignani; Nicholas M Valiante
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

10.  Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.

Authors:  Chien-Te K Tseng; Gary R Klimpel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  69 in total

1.  Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.

Authors:  Kathleen McCaffrey; Irene Boo; Kevin Tewierek; Mark L Edmunds; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus.

Authors:  Holly Freedman; Michael R Logan; Darren Hockman; Julia Koehler Leman; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

Authors:  Kathleen McCaffrey; Irene Boo; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

4.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Authors:  Adam Zuiani; Kevin Chen; Megan C Schwarz; James P White; Vincent C Luca; Daved H Fremont; David Wang; Matthew J Evans; Michael S Diamond
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

6.  Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014.

Authors:  Heidi E Drummer
Journal:  Ann Transl Med       Date:  2015-05

7.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

8.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Authors:  Julia Bitzegeio; Dorothea Bankwitz; Kathrin Hueging; Sibylle Haid; Christiane Brohm; Mirjam B Zeisel; Eva Herrmann; Marcus Iken; Michael Ott; Thomas F Baumert; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

10.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Authors:  Jeroen Witteveldt; Matthew J Evans; Julia Bitzegeio; George Koutsoudakis; Ania M Owsianka; Allan G N Angus; Zhen-Yong Keck; Steven K H Foung; Thomas Pietschmann; Charles M Rice; Arvind H Patel
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.